Nuvalent (NUVL) Competitors

BeOne Medicines presently has a consensus price target of $390.92, suggesting a potential upside of 25.29%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe BeOne Medicines is more favorable than Nuvalent.

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Nuvalent's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Nuvalent's return on equity.

BeOne Medicines has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

In the previous week, BeOne Medicines had 6 more articles in the media than Nuvalent. MarketBeat recorded 16 mentions for BeOne Medicines and 10 mentions for Nuvalent. BeOne Medicines' average media sentiment score of 0.54 beat Nuvalent's score of 0.43 indicating that BeOne Medicines is being referred to more favorably in the media.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuvalent has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Nuvalent has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Nuvalent's return on equity.

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Moderna had 2 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Moderna and 10 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.43 beat Moderna's score of 0.34 indicating that Nuvalent is being referred to more favorably in the media.

Nuvalent presently has a consensus target price of $127.73, indicating a potential upside of 3.04%. Moderna has a consensus target price of $38.27, indicating a potential downside of 38.10%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than Moderna.

Nuvalent has higher earnings, but lower revenue than Moderna. Nuvalent is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Nuvalent has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Nuvalent's return on equity.

Roivant Sciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, Nuvalent had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Nuvalent and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.37 beat Nuvalent's score of 0.43 indicating that Roivant Sciences is being referred to more favorably in the media.

Roivant Sciences has higher revenue and earnings than Nuvalent. Roivant Sciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential downside of 2.66%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than Roivant Sciences.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nuvalent currently has a consensus price target of $127.73, indicating a potential upside of 3.04%. Insmed has a consensus price target of $211.05, indicating a potential upside of 94.84%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Nuvalent.

Nuvalent has higher earnings, but lower revenue than Insmed. Nuvalent is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Nuvalent's return on equity of -40.11% beat Insmed's return on equity.

Nuvalent has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

97.3% of Nuvalent shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Insmed had 4 more articles in the media than Nuvalent. MarketBeat recorded 14 mentions for Insmed and 10 mentions for Nuvalent. Insmed's average media sentiment score of 0.85 beat Nuvalent's score of 0.43 indicating that Insmed is being referred to more favorably in the news media.